Indivior Pharmaceuticals, Inc.
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.2B
- Net income
- $210.0M
- Total assets
- $1.2B
- Market cap
- $4.4B
- Gross margin
- 80.2%
- Operating margin
- 21.1%
- Net margin
- 16.9%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $1.2B
- Cost of revenue
- $246.0M
- Gross profit
- $994.0M
- Operating expenses
- $732.0M
- Operating income
- $262.0M
- Income tax
- $29.0M
- Net income
- $210.0M
- EPS (basic)
- $1.68
- EPS (diluted)
- $1.64
Balance sheet
- Total assets
- $1.2B
- Current assets
- $652.0M
- Total liabilities
- $1.3B
- Current liabilities
- $914.0M
- Shareholders’ equity
- -$98.0M
Cash flow
- Operating cash flow
- -$27.0M
- Investing cash flow
- -$66.0M
- Financing cash flow
- -$30.0M
- Net cash flow
- -$123.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.4B
- P/E ratio
- 22.8
- EPS (diluted)
- $1.64
- Shares outstanding
- 118.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 24, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $210.0M in FY2025.
- Gross margin of 80.2%, net margin 16.9%.
- Trading 8% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 22.8.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Indivior Pharmaceuticals, Inc..
Write a review
News about Indivior Pharmaceuticals, Inc.
News & sentiment via Polygon.io
